U.S. clinic visits are down. IDEXX revenue is up 10%. The contradiction tells you everything about where veterinary economics is heading.
IDEXX Laboratories reported second-quarter revenue of $1.217 billion on 4 August 2026, a 10% increase over the prior year and 9% on an organic basis. Companion Animal Group (CAG) diagnostics recurring revenue grew 11% as reported and 10% organically. The numbers are striking because they arrived alongside internal data showing declining veterinary clinic visits in the United States.
What IDEXX Actually Delivered in Q2
The headline figures are clean:
- Total revenue: $1,217 million (+10% reported, +9% organic)
- CAG revenue: +9% reported and organic
- CAG Diagnostics recurring revenue: +11% reported, +10% organic
- VetLab consumables: +15% reported, +14% organic
- Reference laboratory services: +11% reported, +10% organic
- EPS: $4.27 (+18% reported, +15% comparable)
- Gross margin: 64.0% (+140 basis points)
- Operating margin: 35.0% (+140 basis points)
The company also narrowed its full-year 2026 revenue guidance to a range of $4,700 million to $4,745 million, lifting the midpoint by $5 million despite a $15 million foreign-exchange headwind. Management raised organic growth guidance to 8.5%–9.7% and CAG Diagnostics recurring revenue organic growth to 9.5%–10.7%.
Why This Matters: The Clinic-Traffic Paradox
IDEXX's own earnings materials acknowledged a softening in U.S. clinic visit volumes. Yet the company grew revenue double digits. The explanation lies in the shift from transaction-based to instrument-based diagnostics.
When a practice owns an IDEXX inVue Dx, Catalyst, or VetLab suite, testing becomes embedded in the workflow. Every sick-patient workup, every pre-anaesthetic screen, every wellness panel runs on installed instruments that consume reagents and consumables. The revenue model is no longer tied to how many puppies walk through the door. It is tied to how deeply diagnostics are integrated into clinical decision-making.
In Q2, the inVue Dx installed base crossed 9,000 instruments globally, with more than 1,600 placements during the quarter alone. Each placement creates a multi-year consumable revenue stream. VetLab consumables grew 14% organically. Reference laboratory services, which capture send-out testing, grew 10% organically.
This is what a recurring-revenue business looks like in veterinary medicine. Even when appointment books thin, the instruments already in place keep generating test volume.
Where the Growth Came From
International markets outpaced the U.S. CAG Diagnostics recurring revenue grew 14% reported and 12% organic outside the United States, compared with 10% reported and organic growth domestically. The international premium instrument installed base is expanding faster, and testing penetration in newer markets is still climbing from a lower base.
Software and imaging are accelerating. Veterinary software, services, and diagnostic imaging systems grew 12% reported and organic. Diagnostic imaging delivered another record quarter of installations, led by the ImageVue DR50 Plus. Cloud-native software growth is pulling through subscription revenue and creating tighter practice-management integration.
Rapid assays are flat. Rapid assay revenue increased only 1% reported and organic. The company attributed this to a modality shift: adoption of the Catalyst Pancreatic Lipase Test is moving some testing from rapid assays to chemistry platforms. This is a technical footnote with strategic significance. It shows IDEXX is willing to cannibalise its own rapid-assay line to drive higher-value instrument-based testing.
Capital instrument revenue declined 20% organically. This is not a weakness. It is the inevitable comparison against Q2 2025, when the inVue Dx launched broadly and generated a surge of capital sales. Current-period instrument revenue still benefited from over 1,600 inVue Dx placements, but the year-over-year comp was brutal.
The Margin Story
Gross margin expanded 140 basis points to 64.0%, driven by volume leverage in recurring revenue, operational productivity, and net price realisation. Operating margin expanded by the same 140 basis points to 35.0%, even as operating expenses grew 10% to fund commercial expansion and innovation.
CEO Mike Erickson described the performance as "durable, compounding growth." The phrase is relevant. Durable growth in diagnostics does not depend on a single product launch or a temporary pandemic pet boom. It depends on installed base, utilisation rates, and pricing power.
What This Means for Veterinary Practices
For practice owners, the IDEXX numbers are a signal about two competing pressures.
Pressure one: Clinic traffic is soft. The post-pandemic pet-acquisition surge has normalised, and economic uncertainty is causing some owners to defer non-urgent visits. Revenue per transaction must rise to offset flat or declining visit counts.
Pressure two: Diagnostic intensity is rising. IDEXX's growth in consumables and reference-lab volume means practices are running more tests per patient. This can be clinically justified—better diagnostics lead to better outcomes—but it also raises questions about affordability and client compliance.
The practices that navigate this successfully will be the ones that use diagnostics as a clinical tool first and a revenue driver second. Clients who trust that every test serves their pet's health will accept higher invoice totals. Clients who suspect up-selling will push back.
The Competitive Landscape
IDEXX's results stand in sharp contrast to Zoetis, which reported a 6% organic decline in global companion-animal revenue in the same quarter. The divergence suggests that diagnostics is currently a more defensive segment than therapeutics and preventive products.
There are structural reasons for this. Diagnostic instruments create switching costs. A practice that has invested in staff training, workflow integration, and client education around in-house testing will not rip out its IDEXX suite because of a temporary downturn. By contrast, a client can easily defer a vaccine or delay a prescription refill.
FAQ
How can IDEXX grow if clinic visits are declining?
Revenue is driven by testing utilisation per visit and the installed instrument base, not just visit count. More tests per patient plus an expanding global instrument footprint offset softer U.S. traffic.
What is the IDEXX inVue Dx?
It is a premium in-house chemistry and immunoassay analyser. IDEXX placed over 1,600 units in Q2 2026, bringing the global installed base above 9,000 instruments. Each placement generates recurring consumable revenue.
Are rapid assays becoming obsolete?
Not obsolete, but partially displaced. The Catalyst Pancreatic Lipase Test is shifting some testing from rapid assays to chemistry platforms. Rapid assays still grew 1%, so demand persists for point-of-care screening.
Is IDEXX raising prices?
Net price realisation contributed to gross margin expansion, but volume growth was the primary driver. The company did not disclose specific pricing changes.
What should practices watch in the second half of 2026?
IDEXX narrowed revenue guidance and raised the organic growth midpoint, signalling confidence. Practices should monitor their own testing utilisation rates and compare them to IDEXX's reported volume trends.
Sources
IDEXX Laboratories — Second Quarter 2026 Results (Business Wire via Financial Times Markets) (04 August 2026)
IDEXX Q2 2026 Earnings Call Coverage (Yahoo Finance)
StockTitan — IDEXX Laboratories 10-Q Quarterly Report (04 August 2026)